eQ PLC’S HALF YEAR REPORT 2020 – eQ IMPROVED ITS RESULT DESPITE THE CHALLENGING MARKET SITUATION – OPERATING PROFIT GREW BY 7%

eQ PLC HALF YEAR FINANCIAL REPORT
11 August 2020 at 8:00 AM

eQ PLC’S HALF YEAR REPORT 2020 – eQ IMPROVED ITS RESULT DESPITE THE CHALLENGING MARKET SITUATION – OPERATING PROFIT GREW BY 7%

January to June 2020 in brief

  • During the period under review, the Group's net revenue totalled EUR 23.9 million (EUR 22.9 million from 1 Jan. to 30 June 2019).

  • The Group’s net fee and commission income was EUR 24.3 million (EUR 22.5 million).

  • The Group’s net investment income from own investment operations was EUR -0.4 million (EUR 0.4 million), including the return from private equity funds and liquid fixed income funds.

  • The Group’s operating profit grew by 7% to EUR 11.7 million (EUR 11.0 million).

  • The Group’s profit was EUR 9.4 million (EUR 8.8 million).

  • The consolidated earnings per share were EUR 0.24 (EUR 0.23).

  • The net cash flow from the Group’s own private equity fund investment operations was EUR -0.2 million (EUR 0.3 million).

  • The net revenue of the Asset Management segment increased by 9% to EUR 22.7 million (EUR 20.8 million) and the operating profit by 15% to EUR 13.0 million (EUR 11.3 million).

  • The net revenue of the Corporate Finance segment was EUR 1.7 million (EUR 1.8 million) and the operating profit was EUR 0.3 million (EUR 0.4 million).

April to June 2020 in brief

  • In the second quarter, the Group’s net revenue totalled EUR 11.9 million (EUR 11.3 million from 1 April to 30 June 2019).

  • The Group’s net fee and commission income was EUR 12.7 million (EUR 11.3 million).

  • The Group’s net investment income from own investment operations was EUR -0.8 million (EUR 0.0 million), including the return from private equity funds and liquid fixed income funds.

  • The Group’s operating profit was EUR 5.7 million (EUR 5.7 million).

  • The Group’s profit was EUR 4.6 million (EUR 4.6 million).

  • The consolidated earnings per share were EUR 0.12 (EUR 0.12).

Key ratios

1-6/20

1-6/19

Change

4-6/20

4-6/19

Change

1-12/19

Net revenue, Group, M€

23.9

22.9

4%

11.9

11.3

5%

50.6

Net revenue, Asset Management, M€

22.7

20.8

9%

11.4

10.6

8%

44.3

Net revenue, Corporate Finance, M€

1.7

1.8

-4%

1.3

0.7

72%

5.4

Net revenue, Investments, M€

-0.4

0.1

-345%

-1.0

0.0

-4063%

0.8

Net revenue, Group administration and

eliminations, M€

-0.2

0,1

0.2

0.0

0.1

Operating profit, Group, M€

11.7

11.0

7%

5.7

5.7

0%

26.3

Operating profit, Asset Management, M€

13.0

11.3

15%

6.6

6.0

9%

25.4

Operating profit, Corporate Finance, M€

0.3

0.4

-6%

0.4

0.1

351%

1.9

Operating profit, Investments, M€

-0.4

0.1

-345%

-1.0

0.0

-4063%

0.8

Operating profit, Group administration, M€

-1.3

-0.9

-0.4

-0.5

-1.8

Profit for the period, M€

9.4

8.8

7%

4.6

4.6

0%

21.0

Key ratios

1-6/20

1-6/19

Change

4-6/20

4-6/19

Change

1-12/19

Earnings per share, €

0.24

0.23

6%

0.12

0.12

0%

0.55

Equity per share, €

1.33

1.37

-3%

1.33

1.37

-3%

1.70

Cost/income ratio, Group, %

51.0

52.1

-2%

52.3

49.9

5%

48.1

Liquid assets, M€

13.8

12.2

13%

13.8

12.2

13%

32.3

Private equity fund investments, M€

16.1

16.8

-4%

16.1

16.8

-4%

16.2

Interest-bearing loans, M€

0.0

0.0

0%

0.0

0.0

0%

0.0

Assets under management excluding reporting services, € billion

7.0

6.2

13%

7.0

6.2

13%

6.8

Assets under management total, € billion

8.5

10.9

-22%

8.5

10.9

-22%

11.7

Janne Larma, CEO

The second quarter was very strong in the capital market. Share prices rose by about 15 to 20% depending on the market, and the interest rates of above all corporate loans fell strongly. By the beginning of August, the global stock exchange index was only about 6% below the level at the beginning of the year. In the second quarter, the development of economies was strongly negative, however, and uncertainty still prevails. The capital market believes that the COVID-19 pandemic can be kept under control in autumn and the vaccine will be here during the first months of 2021.